Safety and Response after Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE for Neuroendocrine Tumors in Phase 1/2 Prospective Japanese Trial.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepato-biliary-pancreatic sciences"
DOI: 10.1002/jhbp.1101
Abstract: BACKGROUND The present prospective phase 1/2 study aimed to elucidate the efficacy and safety of 177 Lu-DOTATATE (four cycles of 7.4 GBq) in Japanese patients with unresectable, progressive neuroendocrine tumors (NETs). METHODS From April 2018… read more here.
Keywords: dotatate; safety; response; neuroendocrine tumors ... See more keywords
Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-022-05771-3
Abstract: NETTER-R aimed to determine the efficacy, safety and tolerability of 177Lu-DOTATATE in patients with progressive, advanced pancreatic neuroendocrine tumours (panNETs) using retrospective real-world data from multiple sites. This international study retrospectively included patients with panNETs… read more here.
Keywords: dotatate; efficacy safety; dotatate patients; 177lu dotatate ... See more keywords
The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of radiology"
DOI: 10.1016/j.ejrad.2018.11.023
Abstract: PURPOSE Patients with von Hippel-Lindau (VHL) disease may develop various tumors, including neuroendocrine tumors of the pancreas (PNETs) and adrenal, central nervous system and retinal hemangioblastomas, kidney tumors and more. 68Ga-DOTATATE positron emission tomography (PET)/computerized… read more here.
Keywords: dotatate pet; detection; von hippel; dotatate ... See more keywords
Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Gastroenterology"
DOI: 10.1053/j.gastro.2017.11.008
Abstract: BACKGROUND & AIMS Survival times vary among patients with neuroendocrine tumors (NETs) - even among those with the same site, stage, and grade of primary tumor. This makes it difficult to select treatment for patients… read more here.
Keywords: tumor volume; patients neuroendocrine; 68ga dotatate; dotatate ... See more keywords
Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1830286
Abstract: Abstract Background and aims In France, there are approximately 2,400 new cases of neuroendocrine tumors (NETs) annually. Peptide receptor radionuclide therapy with 177Lu-Dotatate plus long-acting repeatable [LAR] octreotide 30 mg has been shown to significantly improve… read more here.
Keywords: octreotide lar; 177lu dotatate; dotatate; midgut nets ... See more keywords
CTNI-53. SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-oncology"
DOI: 10.1093/neuonc/noaa215.219
Abstract: Meningiomas are the most common primary intracranial neoplasm. Once surgical and radiotherapeutic options are exhausted, there are no effective medical treatments available. A majority of meningiomas express somatostatin receptor 2 (SSTR2), representing a promising treatment… read more here.
Keywords: meningiomas; treatment; 177lu dotatate; dotatate ... See more keywords
The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000019304
Abstract: Abstract Background: Somatostatin analog therapies showed great potential for patients suffering advanced neuroendocrine tumors (NETs). This study was aimed to evaluate the therapeutic efficacy of 177Lu-DOTATATE/DOTATOC (177Lu-octreotate/octreotide) peptide receptor radionuclide therapy (PRRT) in advanced or… read more here.
Keywords: dotatate; therapeutic efficacy; advanced neuroendocrine; response ... See more keywords
177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001103
Abstract: OBJECTIVE Advanced pancreatic neuroendocrine tumors (pNETs) present a therapeutic challenge with targeted therapies like Everolimus and Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) showing beneficial effects in various cohort studies and randomized trials. Currently there is… read more here.
Keywords: dotatate; therapy; meta analysis; everolimus advanced ... See more keywords
The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE
Sign Up to like & getrecommendations! Published in 2023 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001693
Abstract: Objective The aim of this study is to evaluate the prognostic role of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and quantitative 68Ga-DOTATATE PET/computed tomography parameters such as maximum standardized uptake value (SUVmax), mean… read more here.
Keywords: treated 177lu; 177lu dotatate; dotatate; 68ga dotatate ... See more keywords
177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000002219
Abstract: Introduction Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by… read more here.
Keywords: refractory differentiated; 177lu dotatate; differentiated thyroid; dotatate ... See more keywords
Distinct Imaging Characteristics of Different Metastases From Primary Prostate Adenocarcinoma and Rectal Carcinoid Tumor on 18F-Fluciclovine and 68Ga-DOTATATE PET/CT.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000002358
Abstract: A 71-year-old man with history of prostate cancer is evaluated for rising prostate-specific antigen. The patient also has a history of rectal well-differentiated neuroendocrine tumor. On F-fluciclovine PET/CT, 2 retroperitoneal lymph nodes exhibited intense fluciclovine… read more here.
Keywords: dotatate; fluciclovine; dotatate pet; tumor ... See more keywords